Indian regulators order Sun Pharma to halt eye-drug production at Assam plant

Reuters reports in The Economic Times that Indian regulators issued the August 20 order after a joint inspection found failures in Sun Pharma's quality-management system. The company had voluntarily recalled about 11 eye-care brands in July. Regulators sought more information on the recall of 332 batches, and an official told Reuters that Sun Pharma's compliance report is under review. It remains unclear whether all recalled products were contaminated.